Fuzzy Laws Complicate Tighter Indian Online Pharmacy Rules
This article was originally published in PharmAsia News
The Maharashtra FDA has been sued by a few online pharmacies that claimed to have followed proper procedures in shipping products for valid prescriptions. Under pressure from international agencies, the central regulatory agency is calling a meeting to prevent online pharmacies from sending out products. But vague laws make it complicated.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.